F-18-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10386445" target="_blank" >RIV/00216208:11140/18:10386445 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/18:10386445
Result on the web
<a href="https://doi.org/10.21873/anticanres.12705" target="_blank" >https://doi.org/10.21873/anticanres.12705</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.12705" target="_blank" >10.21873/anticanres.12705</a>
Alternative languages
Result language
angličtina
Original language name
F-18-Fluorocholine PET/MRI in Restaging of Prostatic Carcinoma in Relation to PSA Level and Detection of Active Disease
Original language description
Aim: To evaluate our own experience with F-18-fluoromethylcholine-(FCH)-positron-emission tomography combined with magnetic resonance imaging (PET/MRI) in restaging of patients with prostatic carcinoma and elevated serum prostate-specific antigen (PSA) level. Patients and Methods: The analysis was performed on a sample of 100 male patients who underwent F-18-FCH-PETIMRI, with a mean age of 63.2 years (range=47-78 years). The imaging was performed using an integrated PET/MRI hybrid system after intravenous application of F-18-FCH at a dose of 1.25 MBq/kg. The number and sites of pathological accumulation of FCH related to local recurrence, nodal spread and skeletal metastases were compared to corresponding MRI findings; furthermore, the relation of PSA level and presence of FCH accumulation in tumorous tissue was assessed; finally we correlated the findings of different sites of metastatic involvement. Results: In patients with a PSA level up to 2 ng/ml, accumulation in tumorous tissue of local recurrence or metastases was found in 83.33% in cases of biochemical relapse, and in patients with PSA level above 5 ng/ml in 100% of cases. In general, we found any finding explained rise of PSA level in 94% of patients. Conclusion: F-18-FCH-PETIMRI using an integrated system with 1,25 MBq/kg dosing of FCH is a valuable tool in evaluation of restaging in patients with prostatic carcinoma, with high detection rate even in those with a low serum PSA level.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30224 - Radiology, nuclear medicine and medical imaging
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Anticancer Research
ISSN
0250-7005
e-ISSN
—
Volume of the periodical
38
Issue of the periodical within the volume
7
Country of publishing house
GR - GREECE
Number of pages
5
Pages from-to
4139-4143
UT code for WoS article
000449943500044
EID of the result in the Scopus database
2-s2.0-85049771573